LTRN Lantern Pharma
- 6.180
- -0.090-1.44%
Lantern Pharma News
Lantern Pharma(LTRN.US) 10% Shareholder Sells US$189.1K in Common Stock
$Lantern Pharma(LTRN.US)$ 10% Shareholder Fletcher Aaron G.L. sold 30,000 shares of common stock on May 23, 24, 2024 at an average price of $6.3 for a total value of $189.1K. This transaction involves
Lantern Pharma Inc files for up to $150 million hybrid shelf — SEC filing
Lantern Pharma Inc files for up to $150 million hybrid shelf — SEC filing
Express News | Lantern Pharma Inc Files for Mixed Shelf of Upto $150 Mln- SEC Filing
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. Harrow (NASDAQ
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLantern Pharma (NASDAQ:LTRN) shares rose 14.3% to $7.04 during Friday's after-market session. The company's market cap stands at $75.7 million. As per the press release, Q1 earnings came out ye
Lantern Pharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.
Lantern Pharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Lantern Pharma (LTRN) and OmniAb (OABI)
Lantern Pharma | 10-Q: Quarterly report
Lantern Pharma (LTRN.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.51 dollars, previous value was -0.36 dollars, and expected value was -0.43 dollars.
Lantern Pharma (LTRN.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.51 dollars, previous value was -0.36 dollars, and expected value was -0.43 dollars.
Lantern Pharma Q1 2024 GAAP EPS $(0.51) Misses $(0.43) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.43) by 18.6 percent. This is a 41.67 percent decrease over losses of $(0.
Lantern Pharma and Oregon Partner to Develop Cancer Treatment
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
XCE853 is Oregon Therapeutic's first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 P.m. ET
Q1 2024 Earnings Results & Corporate Updates Webcast to be held Thursday, May 9th, 4:30 p.m. ET, register for webcast here, or at the link provided below. DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc.
Form 144 | Lantern Pharma(LTRN.US) Insider Proposes to Sell 291.55K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 26, $Lantern Pharma(LTRN.US)$ Insider Bios Fund II NT, LP intends to sell 54,597 shares of its common stock on Apr 29, with a total market value of approximately $291.55K.
Form 144 | Lantern Pharma(LTRN.US) Insider Proposes to Sell 2.18 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 26, $Lantern Pharma(LTRN.US)$ Insider Bios Fund II QP, LP intends to sell 407.85K shares of its common stock on Apr 29, with a total market value of approximately $2.18 mil
Form 144 | Lantern Pharma(LTRN.US) Insider Proposes to Sell 666.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 26, $Lantern Pharma(LTRN.US)$ Insider Bios Fund II, LP intends to sell 124.89K shares of its common stock on Apr 29, with a total market value of approximately $666.9K. B
Form 144 | Lantern Pharma(LTRN.US) Insider Proposes to Sell 1.16 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 26, $Lantern Pharma(LTRN.US)$ Insider Bios Fund I QP, LP intends to sell 217.55K shares of its common stock on Apr 29, with a total market value of approximately $1.16 mill
Form 144 | Lantern Pharma(LTRN.US) Insider Proposes to Sell 1.99 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 26, $Lantern Pharma(LTRN.US)$ Insider Bios Fund I, LP intends to sell 371.95K shares of its common stock on Apr 29, with a total market value of approximately $1.99 million
Lantern Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 — HC Wainwright & Co. Reiterates → Neutral 08/10/2023 103.7% EF Hutton → $11 Reiterates Buy →
Analysis
Price Target
No Data
